NewInsight: Anthropic's IPO price against 48 tech IPOs since 1997

SpyGlass Pharma SGP

SpyGlass Pharma listed on Nasdaq on 6 Feb 2026 and is not in the S&P 500. It is worth $1.0 billion. Its price history starts on 6 Feb 2026. Its board has 10 directors, 8 of them independent. 3 other officers are on file. At 30 Jun 2026, Ra Capital Management was its largest institutional holder, with 24.0% of the company.

CEO
Patrick H. Mooney
Chair
Malik Y. Kahook
Listed
6 Feb 2026 on Nasdaq, IPO filings and terms
Headquarters
Irvine, CA
Market cap
$1.0B
19 Nov 2026 close
Revenue
-
No annual report yet

Financials

SpyGlass Pharma's market cap since February 2026

Weekly, up to 13 Nov 2026

Mar 2026AprMayJunJulAugSepOctNov$1.1B

Board and leadership

Board and officers

Board from the proxy filed 26 Mar 2026; officers filed up to 30 Sep 2026

NameTitleSinceIndependentCommitteesAge
Directors (10)
Malik Y. KahookChairNot independent 路 since 2019Chair2019No51
Patrick H. MooneyChief Executive OfficerNot independent 路 since 2021Chief Executive Officer2021No52
Ali BehbahaniDirectorIndependent 路 CompensationAffiliate, New Enterprise AssociatesDirectorYesCompensation49
Habib J. DableDirectorIndependent 路 since 2026 路 CompensationDirectorDirector2026YesCompensation56
Michael Dybbs, Ph.D.DirectorIndependent 路 since 2025 路 AuditAffiliate, Samsara BioCapitalDirector2025YesAudit51
Bilal Arshad KhanDirectorIndependent 路 since 2023 路 Compensation (chair), Nominating and Corporate GovernanceChief Executive Officer, New World Medical, Inc.Director2023YesCompensation (chair), Nominating and Corporate Governance45
Kirk G. NielsenDirectorIndependent 路 since 2025 路 AuditManaging Director, Vensana CapitalDirector2025YesAudit52
Elizabeth G. O'FarrellDirectorIndependent 路 since 2025 路 Audit (chair)DirectorDirector2025YesAudit (chair)61
Geoff PardoDirectorIndependent 路 since 2025 路 Nominating and Corporate GovernancePresident and General Partner, Gilde Healthcare US Inc.Other boards: Mainstay Medical HoldingDirector2025YesNominating and Corporate Governance54
Zach Scheiner, Ph.D.DirectorIndependent 路 since 2023 路 Nominating and Corporate Governance (chair)Partner, RA Capital Management, L.P.Other boards: Nkarta Therapeutics and LENZ TherapeuticsDirector2023YesNominating and Corporate Governance (chair)49
Officers (3)
Jean-Frederic ViretChief Financial OfficerLast filed 9 Feb 2026Chief Financial Officer
James Robert Dennewill Jr.Chief Operating OfficerLast filed 9 Feb 2026Chief Operating Officer
Chetan Pratap PujaraChief R&D OfficerLast filed 9 Feb 2026Chief R&D Officer

Owners and trading

Largest institutional holders

Each fund group's share of SpyGlass Pharma. Where a company has several share classes, the share is of its total value.

13F filings for the quarter to 30 Jun 2026

  • Ra Capital Management24.0%
  • Nea Management Company22.1%
  • Sands Capital Alternatives7.5%
  • Samsara Biocapital6.3%
  • BlackRock2.1%

These five hold 62.0% of SpyGlass Pharma.

Insider trades

Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.

Trades from 19 Nov 2025 to 19 Nov 2026

Directors and officers made no open-market sales and bought $83.9 million in 6 purchases in the 12 months to 19 Nov 2026.

DatePersonTitleTypeSharesValue
16 Nov 2026BuyPeter KolchinskyDirectorDirectorBuy1,000$32K
9 Feb 2026BuyPeter KolchinskyDirectorDirectorBuy3,690,000$59M
9 Feb 2026BuyAli BehbahaniDirectorDirectorBuy937,500$15M
9 Feb 2026BuyGeoffrey B. PardoDirectorDirectorBuy312,500$5.0M
9 Feb 2026BuyKirk G. NielsenDirectorDirectorBuy165,000$2.6M
9 Feb 2026BuyBilal Arshad KhanDirectorDirectorBuy135,000$2.2M

Timeline

Leadership changes, layoffs and insider sales

20 Nov 2024 to 20 Nov 2026; insider sales from 19 Nov 2025

0 departures and 1 appointment of directors and officers in the last two years.

Left the company or board 0Appointed 1WARN layoff notices 0Large insider sales 0Jan 2025AprJulOctJan 2026AprJulOct

Events, newest first

Not on file: no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet, no earnings release figures from the last six months and no quarterly results in its SEC XBRL filings.